^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + vactosertib (TEW-7197) (TGF-β RI kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Excerpt:
...In dose escalation phase, 6 DLT evaluable patients whose tumor cell PD-L1 expression less than 25% will be enrolled in each cohort. In dose expansion phase, 45 patients with confirmed PD-L1-positive NSCLC by the Ventana SP263 IHC assay will be enrolled...
Trial ID:
Source:
Title:
363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
Published date:
11/09/2020
Excerpt:
A phase 1b/2a study was conducted to evaluate the combination of vactosertib and durvalumab in patients with advanced NSCLC who progressed after platinum-based chemotherapy….Objective response rate was 30.8% and 40.0% in patients with PD-L1≥1% and ≥25% respectively....The combination of vactosertib and durvalumab has demonstrated a manageable safety profile and encouraging anti-tumor activity as a potential therapeutic strategy in patients with advanced NSCLC.
DOI:
10.1136/jitc-2020-SITC2020.0363
Trial ID:
